Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited AstraZeneca, the manufacturer of ticagrelor (Brilique(®)), to submit evidence on the clinical and cost effectiveness of ticagrelor 60 mg twice daily (BID) in combination with low-dose aspirin [acetylsalicylic acid (ASA)] compared w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouwels, Xavier G. L. V., Wolff, Robert, Ramaekers, Bram L. T., Van Giessen, Anoukh, Lang, Shona, Ryder, Steve, Worthy, Gill, Duffy, Steven, Armstrong, Nigel, Kleijnen, Jos, Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906512/
https://www.ncbi.nlm.nih.gov/pubmed/29344794
http://dx.doi.org/10.1007/s40273-017-0607-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906512/
https://www.ncbi.nlm.nih.gov/pubmed/29344794
http://dx.doi.org/10.1007/s40273-017-0607-0

Ejemplares similares